Penumbra Inc PEN
We take great care to ensure that the data presented and summarized in this overview for Penumbra Inc is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding PEN
View all-
Black Rock Inc. New York, NY4.26MShares$815 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.7MShares$708 Million0.01% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.03MShares$580 Million0.07% of portfolio
-
Champlain Investment Partners, LLC Burlington, VT1.28MShares$246 Million1.46% of portfolio
-
State Street Corp Boston, MA1.23MShares$236 Million0.01% of portfolio
-
William Blair Investment Management, LLC Chicago, IL825KShares$158 Million0.4% of portfolio
-
Clearbridge Investments, LLC New York, NY774KShares$148 Million0.12% of portfolio
-
Rtw Investments, LP New York, NY742KShares$142 Million2.23% of portfolio
-
Geode Capital Management, LLC Boston, MA644KShares$123 Million0.01% of portfolio
-
Congress Asset Management CO644KShares$123 Million0.85% of portfolio
Latest Institutional Activity in PEN
Top Purchases
Top Sells
About PEN
Penumbra, Inc. designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names. In addition, the company offers microcatheter for the delivery of detachable coils and occlusion devices under the LANTERN brand; and detachable, microcatheter-deliverable occlusion devices designed primarily to occlude peripheral vessels under the POD (Penumbra Occlusion Device) brand, as well as immersive computer-based technologies and immersive therapeutics to promote health, motor function, and cognition under the Real Immersive System brand; and a complementary device for use with Ruby Coil and POD for vessel occlusion under the Packing Coil and Packing Coil LP brands. The company sells its products through direct sales organizations and distributors. Penumbra, Inc. was incorporated in 2004 and is headquartered in Alameda, California.
Insider Transactions at PEN
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Sep 20
2024
|
Adam Elsesser CEO and President |
SELL
Open market or private sale
|
Indirect |
15,000
-0.28%
|
$2,955,000
$197.63 P/Share
|
Sep 04
2024
|
Harpreet Grewal Director |
SELL
Open market or private sale
|
Direct |
782
-8.11%
|
$159,528
$204.11 P/Share
|
Sep 03
2024
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
600
-0.16%
|
$123,600
$206.04 P/Share
|
Aug 23
2024
|
Adam Elsesser CEO and President |
SELL
Open market or private sale
|
Indirect |
28,380
-0.39%
|
$5,761,140
$203.94 P/Share
|
Aug 22
2024
|
Adam Elsesser CEO and President |
SELL
Open market or private sale
|
Indirect |
1,620
-0.17%
|
$324,000
$200.0 P/Share
|
Aug 13
2024
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
600
-0.32%
|
$105,600
$176.52 P/Share
|
Jul 17
2024
|
Adam Elsesser CEO and President |
SELL
Open market or private sale
|
Indirect |
15,000
-0.4%
|
$3,015,000
$201.91 P/Share
|
Jul 01
2024
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
600
-0.48%
|
$107,400
$179.42 P/Share
|
Jul 01
2024
|
Don W. Kassing Director |
SELL
Open market or private sale
|
Direct |
170
-14.47%
|
$30,430
$179.99 P/Share
|
Jun 03
2024
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
600
-0.19%
|
$113,400
$189.59 P/Share
|
May 20
2024
|
Adam Elsesser CEO and President |
SELL
Open market or private sale
|
Indirect |
15,000
-0.39%
|
$3,015,000
$201.9 P/Share
|
May 13
2024
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
600
-0.1%
|
$125,400
$209.33 P/Share
|
May 06
2024
|
Arani Bose Director |
SELL
Bona fide gift
|
Indirect |
69,932
-100.0%
|
-
|
Apr 15
2024
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
SELL
Payment of exercise price or tax liability
|
Direct |
193
-0.3%
|
$40,530
$210.19 P/Share
|
Apr 01
2024
|
Don W. Kassing Director |
SELL
Open market or private sale
|
Direct |
170
-12.64%
|
$37,910
$223.18 P/Share
|
Apr 01
2024
|
Johanna Roberts EVP, Gen. Counsel & Secretary |
SELL
Open market or private sale
|
Direct |
600
-0.1%
|
$131,400
$219.96 P/Share
|
Mar 15
2024
|
Maggie Yuen Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
193
-1.45%
|
$42,846
$222.15 P/Share
|
Mar 15
2024
|
Maggie Yuen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,070
+13.45%
|
-
|
Mar 15
2024
|
Lambert Shiu Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
232
-1.13%
|
$51,504
$222.15 P/Share
|
Mar 15
2024
|
Lambert Shiu Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,670
+7.52%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 10.5K shares |
---|---|
Exercise of conversion of derivative security | 19.9K shares |
Open market or private sale | 101K shares |
---|---|
Payment of exercise price or tax liability | 4.16K shares |
Bona fide gift | 81.4K shares |